Compugen (CGEN)
Builds cancer immunotherapies from computationally predicted drug targets.
Something off on this page? Send us feedback.
Develops cancer immunotherapies using the Unigen™ computational platform, which predicts drug targets and biological pathways. Selected outputs are advanced internally or through pharmaceutical partners, combining clinical-stage programs with licensing and royalty interests.
Uses the Unigen™ computational platform to predict drug targets and biological pathways for cancer immunotherapy. The platform combines biological data, internal scientific knowledge, AI/ML predictive algorithms, and a cloud-based knowledgebase, with feedback from preclinical and clinical work enriching that knowledgebase. It is technology-agnostic and AI/ML-enabled, directly linking discoveries to therapeutic drug development.
Advances selected platform outputs internally as clinical-stage immuno-oncology programs and through pharmaceutical partnerships. The business combines therapeutic development with licensing and royalty interests, including Gilead's licensed anti-IL-18 binding-protein antibody program and a royalty interest connected to AstraZeneca's rilvegostomig.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| May 21, 2026 | Leerink Partners | Reiterate | Outperform | $5 |
| Jan 7, 2026 | H.C. Wainwright | Target | $4 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $125.3M · Total debt $3.0M · Total assets $138.4M · Shareholders' equity $88.7M
- Revenue
- $2.6M
- Operating income
- −$8.8M
- Net income
- −$7.0M
No dividends on record.
| Institutions81 holders · as of Mar 31, 2026 | 15.02% | 14.21M ADS | |
| Insiders12 holders · as of Jul 30, 2026 | 0.43% | 406.4K ADS | |
| Strategic holders1 holder · as of Nov 19, 2021 | 5.03% | 4.76M ADS | |
| Otherremainder | 79.52% | 75.18M ADS |
94.55M ADS as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Nikko Asset Management Americas, Inc.Institution | 7.40% | 7.00M | 13G/Afiled Feb 14, 2022 ↗ |
Bristol Myers Squibb CoStrategic | 5.03% | 4.76M | 13Gfiled Nov 19, 2021 ↗ |
Silverarc Capital Management, LLCInstitution | 3.51% | 3.32M ADS | 13Fas of Mar 31, 2026 |
Renaissance Technologies LLCInstitution | 1.73% | 1.63M ADS | 13Fas of Mar 31, 2026 |
Morgan StanleyInstitution | 1.11% | 1.05M ADS | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 9, 2026 | Zurit Levine | officer: SVP, Business Development | −1,875 | $2.50 |
| Apr 24, 2026 | Eran Ophir | director, officer: President and CEO | −5,000 | $3.20 |
| Apr 24, 2026 | Zurit Levine | officer: SVP, Business Development | −2,000 | $3.20 |
| Apr 14, 2026 | Zurit Levine | officer: SVP, Business Development | −2,000 | $2.80 |
| Apr 14, 2026 | Eran Ophir | director, officer: President and CEO | −5,000 | $2.90 |
- Arcus Biosciences
Fc-silent anti-TIGIT development in solid tumors
- BeOne Medicines (ADR)
Global anti-TIGIT and PD-1 combination development
- Agenus
Checkpoint-combination option in refractory ovarian cancer
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Compugen | $2.65 | +1.00% | $248.7M | 7.0 | — | 3.4 | +107.0% |
| Arcus Biosciences | $29.51 | −0.96% | $3.75B | — | — | 32.1 | −74.4% |
| BeOne Medicines (ADR) | $361.00 | −0.21% | $38.66B | 5.0 | 46.1 | 6.7 | +29.6% |
| Agenus | $8.10 | +0.25% | $336.9M | 3.1 | — | 2.5 | +34.3% |
| Median | 4.0 | 46.1 | 6.7 | +29.6% |